GlassScriptPhysician profile
Roger S Harris
NPI 1730188269
$2,622.05
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $870 · 2021: $618 · 2022: $416.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $551.74 | 2019-2022 | |
| Pfizer INC. | $421.45 | 2019-2022 | |
| Amgen INC. | $398.85 | 2019-2022 | |
| Lilly USA, LLC | $304.73 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $268.14 | 2019-2022 | |
| Abbvie INC. | $157.30 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $120.64 | 2019-2021 | |
| Gilead Sciences, INC. | $93.24 | 2019 | |
| Abbott Laboratories | $71.38 | 2021 | |
| Phadia US INC. | $67.61 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.04 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.24 | 2019-2021 | |
| Glaxosmithkline, LLC. | $24.05 | 2020 | |
| Merck Sharp & Dohme LLC | $17.64 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.